Arizona State University scientists say that pulling mice off repeated oxycodone does more than make them act differently. It also dials down key genes that help build and repair myelin, the fatty insulation that wraps nerve fibers, and those molecular shifts show up alongside noticeable changes in social behavior. The peer-reviewed work uses a mouse model of chronic oxycodone exposure followed by spontaneous withdrawal and suggests opioid effects reach beyond neurons to the brain’s support cells. The team argues that oligodendrocytes and myelin remain overlooked pieces of the addiction story.
What the researchers did
The study measured how mice interacted socially, then examined which genes were switched on or off in the medial prefrontal cortex during the first 48 hours of withdrawal. The group found reduced expression of two myelin-related genes, Tcf7l2 and Klk6, according to ASU News. The work, supported by state and federal grants, appears in the journal Pharmacology Biochemistry and Behavior and is listed on PubMed (doi:10.1016/j.pbb.2026.174229). Researchers repeatedly administered oxycodone, then stopped the drug and tracked what happened during withdrawal.
Behavioral signs and early changes
First author Olivia Law told reporters that mice in withdrawal "showed reduced social behavior" roughly 24 to 48 hours after their final oxycodone exposure, a behavioral shift that aligned with lower activity in the myelin-related genes, as reported by KJZZ. Senior author Jessica Verpeut said the results highlight the need to look beyond neurons and pay closer attention to non-neuronal cells when mapping how opioids affect the brain. The authors and accompanying press materials stress that these are preclinical, correlational findings, not proof that myelin changes directly cause specific addiction outcomes in people.
Why myelin matters
Oligodendrocytes produce myelin, which speeds electrical signaling and helps organize circuits involved in impulse control and decision-making. The ASU team proposes that a temporary drop in Tcf7l2 and Klk6 during acute withdrawal could disrupt myelin maintenance or repair in the prefrontal cortex, potentially shifting how reward and self-control circuits operate, according to ASU News. They suggest that therapies aimed at supporting or restoring oligodendrocyte function deserve a closer look as possible add-ons to current approaches.
Local and clinical context
Opioid-related harm remains a major public-health concern in Arizona, where state officials track unintentional and undetermined drug-overdose deaths and use that data to guide prevention efforts. Recent state materials describe ongoing surveillance and response work, and AZDHS documents show continued investment in treatment and harm-reduction strategies. In clinical practice, medications such as methadone and buprenorphine are still considered first-line tools for treating opioid use disorder and easing withdrawal symptoms, according to a recent review in JAMA. Researchers involved with the new study caution that laboratory findings like these do not change standards of care for patients today.
What comes next
The authors say their next move is to test whether interventions that protect or restore oligodendrocyte function can shift withdrawal-related behaviors and to investigate whether similar gene-expression changes show up in humans. Larger animal studies, along with human tissue or brain imaging work, will be needed before any clinical applications are on the table, according to the journal listing on PubMed. For people and families already wrestling with opioid use, experts and state agencies continue to point to evidence-based medications combined with counseling as the strongest proven way to reduce harm right now.
